Complaints Outcomes

Search

Search Results

Search Again
Lee, Billy (Jul 8, 2020)
  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Billy Lee (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996 c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: July 8, 2020

  3. Name of registrant: Billy Lee

  4. Location of Practice: Richmond, BC

  5. Admissions and Acknowledgements:

    The Registrant has admitted and/or acknowledged the following: 

    1. While he was a pharmacist registrant, he was involved with a company known as Quantum Solutions, SRL that sold wholesale quantities of Schedule 1 prescription drugs to pharmacies located in the United States over a period of four years between 2007 and 2011. This conduct was investigated by the United States Attorney’s Office in the Western District of Pennsylvania which resulted in criminal charges being filed against the Registrant and others. The Registrant entered a guilty plea to the charges and was sentenced to pay fines and to three years’ probation commencing July 31, 2018 and ending on July 31, 2021.

    2. The Registrant has acknowledged to CPBC that his involvement with Quantum was a contravention the following legislation (as the legislation existed between 2007 and 2011):

      1. Section 9 of the Pharmacy Operations and Drug Schedule Act, S.B.C. 2003, c. 77 (“PODSA”) (which was prior to April 1, 2009 section 29 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act, R.S.B.C. 1996, c. 363);

      2. Which was then Section 3(5) of Bylaws to PODSA (which was prior to April 1, 2009 section 31(5) of the Bylaws of the Council of the College of Pharmacists of BC (“Council Bylaws”));

      3. Which was then section 90(1)(d) of the Council Bylaws; and

      4. Which was then Value I of the Code of Ethics.

  6. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee wherein the Registrant consented to the following terms (in part):

    1. To not repeat the conduct to which this matter relates;

    2. To successfully complete and pass an ethics course for healthcare professionals;
       
    3. To have a letter of reprimand placed on the College register for a period of five years;
       
    4. To be suspended as a registrant of the College for a period of 90 consecutive days, commencing July 8, 2020; and

    5. To not act as a pharmacy manager, direct or indirect owner of a pharmacy, and preceptor for a period of 180 days from the date that his suspension ends.

  7. Rationale:

    The Inquiry Committee considered that in this case, the misconduct of the Registrant was of a serious nature and that the Registrant should have known that his conduct was unbecoming of a pharmacist.

    The Inquiry Committee considered the totality of the Registrant’s conduct and considered the terms of the Consent Agreement necessary to protect the public as well as send a clear message of deterrence to the profession.

Pharmacist Registrant 43 (Jun 16, 2020)

The Inquiry Committee has reinstated pharmacist registrant’s registration, which had previously been suspended for an indefinite period on April 8, 2020. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act. 


April 8, 2020
(June 12, 2020 - Registration Reinstated)

The Inquiry Committee, pursuant to s. 32.3(3)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective April 8, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Sam, William Byron (Jun 15, 2020)
  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted investigations into the practice of William Byron Sam (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigations by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: June 15, 2020

  3. Name of registrant: William Byron Sam

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    The Registrant has admitted and/or acknowledged the following: 

    1. The Registrant failed to respond in to correspondence from the College, including requests for information from College staff.

    2. The Registrant continued to engage in the practice of pharmacy at a time when his registration was cancelled contrary to s. 3 of the Pharmacists Regulation.

    3. The Registrant operated or permitted the operation of a pharmacy when not authorized under bylaw or by a pharmacy licence contrary to section 7(1) and (3) of the Pharmacy Operations and Drug Scheduling Act (“PODSA”).

    4. The Registrant sold and dispensed drugs to patients without having the correct information for the pharmacy on the label, contrary to section 9 of PODSA and section 9 of the Community Pharmacy Standards of Practice which are Part 1 of Schedule F to the HPA Bylaws. 

  6. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee wherein the Registrant consented to the following terms (in part):

    1. cancellation of his registration,

    2. no right to apply for reinstatement for 3 years, and
       
    3. before submitting an application for reinstatement after 3 years, he must

      • pay a fine of $25,000, and
      • at his own expense, successfully complete all of
        • the College’s Jurisprudence Examination,
        • the Canadian Pharmacy Practice Program (CP3), and
        • the Pharmacy Examining Board of Canada, Pharmacist Qualifying Examination – Part II (OSCE);

       

  7. Rationale:

    There were previous issues with the Registrant regarding unresponsiveness to and disregard for the College and its regulatory requirements and its communications with him.

    The Registrant knowingly engaged in the practice of pharmacy at a time when he was not registered to do so.  He also knowingly operating an unlicensed pharmacy, contrary to the directions of the College.  Serious public risk factors were present within the pharmacy.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession.


June 6, 2019
(June 15, 2020 - Registration Cancelled)

Pursuant to section 35(1)(b) of the Health Professions Act, the Inquiry Committee has ordered a suspension of the registration of registrant William Byron Sam pending completion of an investigation, effective June 6, 2019. The Registrant will not be able to practice pharmacy in the province of British Columbia while his registration is suspended. The Inquiry Committee considered the suspension necessary to protect the public.

The Inquiry Committee was satisfied on the information before it that there is a real risk to the public should this interim order not be put in place. The Registrant was knowingly operating an unlicensed pharmacy, contrary to the directions of the College. Serious public risk indicators were present within the pharmacy. The Registrant continued to display an inexplicable pattern of responsiveness to and disregard for the College and its regulatory requirements and its communications with him.

Note: Suspensions ordered by the Inquiry Committee under section 35(1)(b) of the Health Professions Act are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Pharmacist Registrant 42 (Jun 5, 2020)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective June 5, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


February 25, 2020
(June 5, 2020 - Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on August 14, 2019. Pursuant to Section 32.2(4)(b)(ii) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all treatment plans as recommended by his medical providers.
     
  2. To comply with any and all work plans as advised by his medical providers and/or employers.
     
  3. To comply with every term of his Relapse Prevention Agreement (“RPA”).
     
  4. To be responsible for all costs related to treatment, recovery plans and monitoring his condition.
     
  5. In the event of any interruption to the agreed monitoring schedule set out in the RMA, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption.
     
  6. To not possess or have access to the key(s) to any pharmacy for a minimum 12 month period after his status is changed to “Full Pharmacist – Active”. This limit will be in place until a new Independent Medical Examination (“IME”) is conducted and recommends this restriction be removed.
     
  7. To not be the sole pharmacist on duty while working at any pharmacy for a minimum of 12 months after his status is changed to “Full Pharmacist – Active”. This limit will be in place until a new IME is conducted and recommends this restriction be removed.
     
  8. The Registrant will inform the College in writing, via e-mail, of his places of work as a pharmacist and report any changes to the location of his work within 48 hours of such change. A reportable change to the Registrant’s place of work contemplates both commencement and termination of work.
     
  9. Prior to the commencement of work at any pharmacy, the Registrant shall:

    1. Disclose to the pharmacy manager and/or employer the limits and conditions on his license pursuant to this Consent Agreement;

    2. Ensure that any pharmacy manager and/or employer with whom the Registrant secures work in a pharmacy submits a written statement to the College declaring their awareness of the Registrant’s Consent Agreement and the limits and conditions on the Registrant’s license to practice pharmacy. This statement must be received within 48 hours of securing work and/or within 48 hours of any change of pharmacy manager at the Registrant’s place of work.

The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


August 14, 2016
(February 25, 2020 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective August 14, 2019. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

 

Pharmacy Technician Registrant 5 (May 14, 2020)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacy technician registrant to voluntarily suspend the registration as a pharmacy technician effective May 14, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacy technician registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Sharma, Shiv Kumar (Apr 15, 2020)
  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacist of British Columbia (the “College”) conducted an investigation into the practice of Shiv Kumar Sharma (the “Registrant”), pursuant to section 33(1) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: April 15, 2020

  3. Name of registrant: Shiv Kumar Sharma

  4. Location of Practice: Surrey, BC

  5. Admissions and Acknowledgements: The Registrant has admitted and/or acknowledged the following: 

    1. While he was director and pharmacy manager, pharmacy staff (including himself) altered PharmaNet entries for a patient creating an inaccurate patient record. Additionally, pharmacy staff (including himself) backdated the patient's prescriptions, meaning that the dispensing records for those prescriptions were created on dates later than the dates on which the drugs in question were actually dispensed, contrary to section 35(1) of the Bylaws to the Pharmacy Operations and Drug Scheduling Act; and

    2. The Registrant did not provide truthful or accurate information to the Investigator during the investigation into the matter, contrary to section 19 of the Bylaws to the Pharmacy Operations and Drug Scheduling Act

  6. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms (in part):

    1. To not be a pharmacy manager for a period of twenty-eight (28) days from April 17, 2020 to May 14, 2020;

    2. To not be a preceptor or supervisor of pharmacy students and/or international pharmacy graduates for a period of one year from April 15, 2020 to April 14, 2021;
       
    3. To pay a $1000.00 fine;

    4. To successfully pass the CPBC's Jurisprudence Exam; and

    5. To successfully complete and pass an ethics course designed specifically for health care professionals pass an ethics course for healthcare professionals;​

  7. Rationale:

    The Inquiry Committee considered that in this case, in addition to the serious misconduct, the Registrant placed his patient at significant risk of harm when he altered the patient’s PharmaNet record. His actions were a serious contravention of the standards in the Code of Ethics, and compromised the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee considered the totality of the Registrant’s conduct to be serious, and that he required remediation and a deterrence in order to come into compliance. The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

Pharmacist Registrant 27 (Feb 11, 2020)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on May 12, 2019. Pursuant to Section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all recommendations and treatment prescribed or directed by medical professionals involved in the Registrant's care;
     
  2. To comply with any and all work plans and gradual return to work protocols as advised by the Registrant’s medical professionals and/or employers;
     
  3. To strictly adhere to the Registrant's routine medical monitoring program for the current 3 year period, and then sign an identical agreement for monitoring for an additional 2 years, for a total period of 5 years of monitoring;
     
  4. To not order, handle, prepare, dispense or destroy any narcotic, controlled or targeted substances the Registrant may have access to while being medically monitored;
     
  5. To inform the College in via e-mail of the Registrant’s places of employment as a pharmacist and report any changes to the location of their employment within 48 hours of such change;
     
  6. To inform all managers and employers with whom the Registrant gains employment of the limits and conditions on registration pursuant to the Agreement, if the pharmacy dispenses mood altering drugs;
     
  7. To ensure that all managers and employers with whom the Registrant gains employment submits a written statement to the College declaring their awareness of the limits and conditions on registration pursuant to the Agreement, if the pharmacy dispenses mood altering drugs.

May 12, 2019
(FEBRUARY 11, 2020 - REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective May 12, 2019. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


November 7, 2016

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on June 10, 2016. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) of the Health Professions Act


June 10, 2016
(NOVEMBER 7, 2016 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective June 10, 2016. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Deol, Harpreet Singh (Feb 5, 2020)
  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacist of British Columbia (the “College”) conducted an investigation into the practice of Harpreet Deol (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183. The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the Health Professions Act.

  2. Effective date: February 5, 2020

  3. Name of registrant: Harpreet Singh Deol​

  4. Location of Practice: Abbotsford, BC

  5. Admissions and Acknowledgements:

    Between February 2018 and August 2019, the Registrant took unauthorized medications for his own personal use from the pharmacy for which he was director and pharmacy manager. The medications taken included, but were not limited to, 11,000 tablets and 116,000 millilitres of narcotic drug substances and 200 tablets and 7 vials of controlled drug substances, both of which require an authorized prescription.

    The Registrant did not process or bill these medications on PharmaNet and these medications were reportedly not provided to any other persons. All narcotic and controlled drug inventory was ordered and managed under the Registrant’s credentials and may have contributed to these losses going undetected.

    A College inspection conducted on August 7th, 2019 identified additional deficiencies in the Registrant’s management of the pharmacy and the pharmacy’s overall practice which included, but were not limited to, inaccurate dispensing of Methadone, inadequate/incomplete documentation, a lack of policies and procedures, inadequate record keeping and management of narcotic inventory, and inadequate pharmacy security

  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that include (but are not limited to) the following:

    1. To suspend his registration as a pharmacist for a total of 90 days from February 26, 2020 to May 25, 2020;

    2. To not be pharmacy manager, director, or owner of a pharmacy for a period of three years from May 26, 2020 to May 25, 2023;
       
    3. To not be a preceptor or supervisor of pharmacy students or international pharmacy graduates for a period of three years from May 26, 2020 to May 25, 2023;

    4. In relation to narcotic and controlled drugs, to not place and receive orders, destroy expired inventory, or have signing authority relating to the ordering of such substances for a period of three years from May 26, 2020 to May 25, 2023;

    5. To complete and successfully pass an ethics course for healthcare professionals;

    6. To complete and successfully pass training courses pertaining to the provision of Opioid Agonist Treatment (OAT) to patients and the management of a community pharmacy; and

    7. To pay a fine of $2,500.

  7. Rationale:

    The Inquiry Committee considered that in this case, in addition to the serious misconduct, the Registrant placed himself and his patients at significant risk of harm when he took unauthorized medications for personal use and continued to practice in the capacity of a pharmacist. His actions were a serious contravention of standards in the Code of Ethics, and compromised the public’s trust in the pharmacy profession as a whole.

    The Inquiry Committee therefore determined that the Registrant required serious remediation and deterrence regarding his conduct. After also considering significant mitigating factors, the Inquiry Committee considered the terms of the Consent Agreement appropriate to protect the public, as well as send a clear message of deterrence to the profession.

Bao, Leanne Hong Le (Jan 31, 2020)
  1. Nature of Action: ​The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted an investigation into the practice of Leanne Hong Le Bao (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: January 31, 2020

  3. Name of registrant: Leanne Hong Le Bao

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgements:

    The Registrant has admitted and/or acknowledged the following (in part):

    1. The Registrant was in breach of her previous consented undertakings, which can be considered professional misconduct under section 26 of the HPA;
       
    2. The Registrant did not process methadone prescriptions on PharmaNet prior to dispensing on at least 25 occasions, contrary to section 21(1) now section 35(1) of the Pharmacy Operations and Drug Scheduling Act (“PODSA”), Bylaws;

    3. The Registrant did not ensure appropriate documentation and record keeping relating to Methadone Maintenance Treatment practices, contrary to principle 4.1.3 and 2.1.2 of Professional Practice Policy – 66;

    4. As pharmacy manager, the Registrant did not ensure that the pharmacy’s premise was suitable for operation, contrary to section 2(1)(b)(iv) of PODSA prior to April 1, 2018, section 11(2)(c)(d) now section 25(2)(c)(d) of the PODSA, Bylaws and section 8(a) of the Food and Drugs Act
       
  6. Disposition:

    The Registrant entered into a Consent Agreement with the Inquiry Committee of CPBC, wherein the Registrant consented to the following terms (in part): 

    1. To not be a pharmacy manager until:

      • She has completed Jurisprudence Exam;
      • She has completed “The BC Community Pharmacy Manager Training Program” offered by the British Columbia Pharmacy Association; and
      • She has met with the Deputy Registrar to reflect on her conduct and how she will improve her pharmacy practice going forward.
         
    2. To acknowledge a CPBC follow-up inspection may be conducted within a year; and
       
    3. To pay a $5,000.00 fine.​

  7. Rationale:

    The Registrant consented to undertakings in relation to a previous file. The undertakings in the previous file included the College conducting a follow-up inspection. Upon re-inspection, College investigators observed similar deficiencies, including narcotic counts and reconciliations were not completed, Methadone Maintenance Treatment documentation and record keeping were not appropriately completed, and the Pharmacy premise was not suitable for dispensing. Based on this, the Inquiry Committee determined the Registrant’s practice did not comply with the legislated practice standards and that the Registrant was in breach of her previous Consent Agreement, which can be considered as professional misconduct. The Inquiry Committee considered the Registrant’s conduct to be serious and that the Registrant required remediation and a deterrence in order for her practice to come into compliance.

    The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

McPherson, Joshua Bruce (Jan 31, 2020)

Nature of Action: Pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”), effective January 31, 2020, the Inquiry Committee of the College of Pharmacists of British Columbia has made an order to impose limits and conditions on the pharmacy practice of the registrant Joshua Bruce McPherson (the “Registrant”) during the investigation into the Registrant’s practice.

In addition to restrictions placed on the Registrant’s practice on January 27, 2020 by the Inquiry Committee, the Registrant is restricted from acting as a pharmacy manager as of February 8, 2020.

The Inquiry Committee considered this action necessary to protect the public.

Note: Limits and conditions ordered by the Inquiry Committee under section 35(1)(a) of the HPA are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.


January 27, 2020
(January 31, 2020 - Limits and conditions updated)

Nature of Action: Pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”), effective January 27, 2020, the Inquiry Committee of the College of Pharmacists of British Columbia has made an order to impose limits and conditions on the pharmacy practice of the registrant Joshua Bruce McPherson (the “Registrant”) during the investigation into the Registrant’s practice.

The Registrant will be restricted from providing any Opioid Agonist Treatment services as of February 1, 2020.

The Registrant is restricted from providing emergency prescription refills on narcotic, controlled or targeted drugs as well as zopiclone and zolpidem.

The Inquiry Committee considered this action necessary to protect the public.

Reasons: While practicing as a pharmacist, it is alleged that the Registrant did not comply with the applicable legislation and standards of practice required in order to dispense Opioid Agonist Treatment. While practicing as a pharmacist, it is alleged that the Registrant provided emergency prescription refills without exercising appropriate clinical judgement and supporting documentation.

Note: Limits and conditions ordered by the Inquiry Committee under section 35(1)(a) of the HPA are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Pages